{"title":"Atherogenic index of plasma and risk of reduced eGFR with age-adapted eGFR thresholds in the elderly general population.","authors":"Ruoyu Zhu, Wen Shi, Zhi Du, Dongfei Wang, Jialan Lyu, Zhicheng Pan, Yuxiao Chen, Xiaofang Lou, Jian Yang, Xiaogang Guo","doi":"10.1080/17520363.2026.2763599","DOIUrl":"https://doi.org/10.1080/17520363.2026.2763599","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to evaluate the correlation between atherogenic index of plasma (AIP) and prevalence of reduced estimated glomerular filtration rate (eGFR).</p><p><strong>Methods: </strong>This cross-sectional study included 4885 participants aged ≥60 from southeast China from 13 September 2023 to 30 November 2023. AIP was calculated as the logarithmic ratio (base 10) of triglycerides to high-density lipoprotein cholesterol. This study used categorical age-adapted eGFR thresholds in two age groups to analyze: <60 mL/min/1.73 m<sup>2</sup> for those aged 60-65 years old and <45 mL/min/1.73 m<sup>2</sup> for those over 65 years old. The category-free analysis was performed to corroborate whether AIP enhanced the ability to estimate reduced eGFR.</p><p><strong>Results: </strong>The prevalence of reduced eGFR in the general population aged ≥60 was 2.7%. After adjustment, each SD increase in AIP was associated with a 52% additional risk for reduced eGFR. When dividing AIP into quartiles, the top quartile had a 2.95 times higher risk than the bottom quartile. Subgroup analysis revealed that the association remained robust against several risk factors for renal damage.</p><p><strong>Conclusion: </strong>This study reveals an association between AIP and reduced eGFR with age-adapted eGFR thresholds, independent of conventional risk factors.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2026-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149417073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bin Luo, Jing Yang, Hui Lu, Xinlu Yao, Peifu Wang, Jichen Du
{"title":"Immune-inflammatory indices and a serum surrogate composite score of blood-brain barrier injury in acute ischemic stroke.","authors":"Bin Luo, Jing Yang, Hui Lu, Xinlu Yao, Peifu Wang, Jichen Du","doi":"10.1080/17520363.2026.2757734","DOIUrl":"https://doi.org/10.1080/17520363.2026.2757734","url":null,"abstract":"<p><strong>Background: </strong>Systemic inflammation is linked to blood-brain barrier (BBB) breakdown in acute ischemic stroke (AIS), but the association between peripheral immune-inflammatory indices and BBB permeability remains unclear.</p><p><strong>Methods: </strong>We enrolled 286 AIS patients within 24 h of onset. Five indices (NLR, PLR, LMR, SII, SIRI) were calculated from admission samples. A serum surrogate score integrating MMP-9, S100B, and BDNF (not calibrated against DCE-MRI or CSF albumin quotient) indicated BBB injury.</p><p><strong>Results: </strong>All five indices correlated significantly with the surrogate score after Bonferroni correction (all adjusted <i>p</i> < 0.01). In adjusted regression, SII (β = 0.452, <i>p</i> < 0.001) and NLR (β = 0.387, <i>p</i> < 0.001) were independent correlates. SII had the highest adjusted AUC (0.768; 95% CI 0.711-0.819), indicating moderate discrimination for high surrogate-defined BBB injury. The SII-score association was stronger in patients with NIHSS ≥ 8 (P~interaction~=0.024), with a similar non-significant trend for infarct volume ≥15 mL (P~interaction~=0.067). SII correlated positively with MMP-9 (<i>r</i> = 0.402, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>SII and NLR are independently associated with a serum surrogate score of BBB injury in AIS. SII shows moderate discrimination and may aid early risk stratification, pending validation against gold-standard measures. The SII-MMP-9 correlation suggests shared inflammatory pathways warranting further study.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-13"},"PeriodicalIF":2.1,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of serum isatin as a potential biomarker in patients with neuropsychiatric disorders: a prospective observational study.","authors":"Debasish Hota, Archana Mishra, Amiya Shaju, Biswa Ranjan Mishra, Debadatta Mohapatra, Rituparna Maiti","doi":"10.1080/17520363.2026.2760985","DOIUrl":"https://doi.org/10.1080/17520363.2026.2760985","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate serum isatin, an endogenous stress-responsive indole, as a diagnostic, pharmacodynamic and prognostic biomarker in major depressive disorder (MDD), seizures and schizophrenia.</p><p><strong>Patients and methods: </strong>In this prospective observational study, 120 participants (30 each with MDD, seizures or schizophrenia, and 30 healthy controls) were enrolled. Serum isatin was measured by HPLC at baseline and, in patients, after 12 weeks of standard pharmacotherapy.</p><p><strong>Results: </strong>Baseline isatin was significantly higher in all disease groups than in controls and discriminated each disease with near-perfect accuracy (AUC 0.996-1.000). Isatin decreased significantly in all three disease groups after 12 weeks, most in schizophrenia (-23.91 ± 15.43 nmol/L), and responders showed greater reductions than non-responders in every disease. In seizures, baseline isatin predicted non-response (AUC 0.814; 95% CI 0.637-0.991). Mediation analysis identified competing pathways: higher baseline isatin drove greater isatin reduction while independently impairing response. Baseline isatin was the strongest predictor of follow-up isatin (β = 0.814, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Serum isatin shows promise as a transdiagnostic pharmacodynamic biomarker and as a prognostic marker in seizures, with its change being more informative than absolute levels. Validation in larger, multicentre longitudinal studies is needed before clinical use.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hiba Muwafaq Saleem, Ahmed T Enad, Reem Alaulddin Jameel, Hussein Riyadh Abdul Kareem Al-Hetty, Mustafa Nuhad Al-Darraji
{"title":"Alterations in ferroptosis-associated biomarkers and immune dysregulation in diabetic osteoporotic patients.","authors":"Hiba Muwafaq Saleem, Ahmed T Enad, Reem Alaulddin Jameel, Hussein Riyadh Abdul Kareem Al-Hetty, Mustafa Nuhad Al-Darraji","doi":"10.1080/17520363.2026.2760338","DOIUrl":"10.1080/17520363.2026.2760338","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis has recently been identified as a potential mechanism linking metabolic dysfunction to diabetic osteoporosis (DOP). Nevertheless, clinical evidence regarding ferroptosis-associated biomarkers in DOP remains limited.</p><p><strong>Methods: </strong>In this case-control study, markers of glucose metabolism, iron homeostasis, oxidative stress, antioxidant status, inflammation, and ferroptosis were assessed in 185 participants, including 110 patients with DOP and 75 controls.</p><p><strong>Results: </strong>Patients with DOP showed significant metabolic alterations, including increased fasting glucose, insulin, HbA1c, HOMA-IR, serum iron, ferritin, PTGS2, and ACSL4 levels. Oxidative stress markers (MDA, TBARS, and GSSG) and inflammatory cytokines (IL-6, IL-1β, TNF-α, and IL-10) were also increased, whereas antioxidant markers (GSH, TAC, and GPX4) were decreased. Ferritin and HOMA-IR were independently associated with PTGS2 levels. PTGS2 and ferritin demonstrated good exploratory discriminatory performance between patients with DOP and controls, while the combined biomarker model showed the highest exploratory discriminatory performance.</p><p><strong>Conclusion: </strong>Patients with DOP revealed alterations to metabolic state, oxidative balance, antioxidant defenses, inflammatory signaling, and systemic iron homeostasis. The exploratory ROC results indicate discrimination between patients with DOP and controls; however, DOP-specific diagnostic performance cannot be determined due to the absence of T2DM-only and osteoporosis-only comparator groups.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Faegheh Bahri, Mohammad Erfan Norouzmahani, Mojgan Moshrefi, Sina Habibi, Iman Rad, Gholamreza Asadikaram, Sanaz Faramarz, Danial Abdollahdokht, Victoria Habibzadeh, Shirin Orandi, Mohammad Hadi Nematollahi
{"title":"Oxidative-antioxidant imbalance in female infertility: evaluation of serum biomarkers and their diagnostic potential.","authors":"Faegheh Bahri, Mohammad Erfan Norouzmahani, Mojgan Moshrefi, Sina Habibi, Iman Rad, Gholamreza Asadikaram, Sanaz Faramarz, Danial Abdollahdokht, Victoria Habibzadeh, Shirin Orandi, Mohammad Hadi Nematollahi","doi":"10.1080/17520363.2026.2753292","DOIUrl":"https://doi.org/10.1080/17520363.2026.2753292","url":null,"abstract":"<p><strong>Aims: </strong>Oxidative stress (OS) is implicated in the pathogenesis of female reproductive disorders and may contribute to infertility. This study evaluated serum OS-related biomarkers and their diagnostic potential in women with different causes of infertility.</p><p><strong>Materials and methods: </strong>In this case-control study, 300 women were enrolled, including 250 infertile women with diminished ovarian reserve (DOR), polycystic ovary syndrome (PCOS), tubal factor infertility (TF), endometriosis (EM), or unexplained infertility (UI), and 50 fertile controls. Serum total antioxidant capacity (TAC), superoxide dismutase (SOD) activity, iron (Fe), copper (Cu), and reproductive hormone concentrations were measured. Correlation and receiver operating characteristic (ROC) curve analyses were performed.</p><p><strong>Results: </strong>Compared with fertile controls, infertile women had significantly lower serum TAC levels (<i>p</i> < 0.001) and higher Fe concentrations (<i>p</i> < 0.001). SOD activity and Cu concentrations were also significantly higher among infertile women (<i>p</i> < 0.05). ROC curve analysis showed the best diagnostic performance of TAC to distinguish all subgroups of infertility from fertile controls. Serum Fe levels were negatively and significantly correlated with the levels of TAC.</p><p><strong>Conclusion: </strong>An imbalance between oxidative and antioxidative systems is associated with female infertility. TAC demonstrated the highest discriminative ability and may represent a useful noninvasive biomarker of infertility-associated OS.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-15"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ewelina Krzywinska, Michal Sobecki, Mateusz W Kucharczyk
{"title":"CGRP levels in autoimmune diseases: a systematic review and meta-analysis of its potential role as a biomarker.","authors":"Ewelina Krzywinska, Michal Sobecki, Mateusz W Kucharczyk","doi":"10.1080/17520363.2026.2756984","DOIUrl":"https://doi.org/10.1080/17520363.2026.2756984","url":null,"abstract":"<p><strong>Aim: </strong>This systematic review and meta-analysis aimed to quantitatively evaluate calcitonin gene-related peptide (CGRP) concentrations across autoimmune diseases (psoriasis, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis) and assess its clinical utility as a neuro-immune biofluid biomarker.</p><p><strong>Materials and methods: </strong>PRISMA-compliant meta-analyses using random-effects models calculated standardized mean differences (SMDs, Hedges' g) from major databases, evaluating circulating biofluids (serum/plasma; 10 studies, 16 cohorts) both overall across all selected autoimmune diseases and stratified by individual disease entities, separately from localized compartments.</p><p><strong>Results: </strong>Primary synthesis of circulating biofluids (533 cases, 363 controls) showed significant systemic CGRP elevation in autoimmune conditions (SMD = 0.63, 95% CI: 0.46-0.80, <i>p</i> < 0.0001; I<sup>2</sup> = 14.4%). Subgroup analyses confirmed elevated circulating CGRP in rheumatoid arthritis (SMD = 0.72), psoriasis (SMD = 0.73), and IBD (SMD = 0.57). Multiple sclerosis showed elevated serum CGRP during progressive phases (SMD = 1.06) versus unchanged CSF levels (SMD = 0.04). Trim-and-fill analysis confirmed estimate stability (adjusted SMD = 0.58).</p><p><strong>Conclusion: </strong>Circulating CGRP is elevated across specific autoimmune pathologies, functioning as a dynamic indicator of active neuro-immune inflammation rather than a static universal marker. Clinical implementation requires prospective, longitudinal studies and standardized, isoform-specific quantification assays.</p><p><strong>Prospero registration number: </strong>CRD420261458044.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-16"},"PeriodicalIF":2.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F I Lang, J Hupf, M Schlossbauer, S Staudner, S Leininger, M Vogel, R Allgaier, S Wallner, R Burkhardt, M Zimmermann, U Hubauer, A Luchner, L Maier, C Jungbauer
{"title":"Blood and urinary NT-proBNP: atrial fibrillation-associated patterns and cardiac dysfunction in acute chest pain.","authors":"F I Lang, J Hupf, M Schlossbauer, S Staudner, S Leininger, M Vogel, R Allgaier, S Wallner, R Burkhardt, M Zimmermann, U Hubauer, A Luchner, L Maier, C Jungbauer","doi":"10.1080/17520363.2026.2756994","DOIUrl":"https://doi.org/10.1080/17520363.2026.2756994","url":null,"abstract":"<p><strong>Introduction: </strong>NT-proBNP is the gold-standard biomarker for diagnosing and monitoring congestive heart failure (CHF); however, its role in detecting atrial fibrillation (AFib) is gaining attention. This study assessed the influence of aberrant cardiac rhythms on plasma NT-proBNP (pNT) considering urinary NT-proBNP (uNT) as a noninvasive alternative in selected clinical scenarios.</p><p><strong>Methods: </strong>In 824 patients presenting with chest pain at the emergency department of the University Hospital of Regensburg, pNT was assessed. A subset of 355 patients additionally provided uNT.</p><p><strong>Results: </strong>Both pNT and uNT were significantly increased in AFib, and lesser in atrial flutter (AFlut) and right ventricular (RV) pacing compared to SR (each <i>p</i> < 0.05). A pNT cutoff of 900 pg/mL yielded 74% sensitivity and 83% specificity for discriminating AFib from SR (AUC = 0.85). In multivariate regression, pNT or uNT and history of AFib were independent predictors of AFib (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Both pNT and uNT are significantly elevated in AFib, and to a lesser extent AFlut, and RV pacing independently of heart failure. These findings align with prior observations and provide further evidence supporting adequately powered prospective studies to evaluate rhythm-adjusted diagnostic thresholds for CHF in AFib. In addition, uNT may complement pNT when venous access is difficult or serial remote monitoring is required.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-14"},"PeriodicalIF":2.1,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic significance of fibrinogen-to-albumin ratio in patients with urological cancers: a meta-analysis.","authors":"Minming Wang, Yue Yang, Jianglv Zhang, Fan Yang","doi":"10.1080/17520363.2026.2754287","DOIUrl":"https://doi.org/10.1080/17520363.2026.2754287","url":null,"abstract":"<p><strong>Aims: </strong>The fibrinogen-to-albumin (FAR) ratio has been investigated as a predictor of the survival of patients with UCs (urological cancers), but definite conclusions are lacking. Therefore, this meta-analysis was performed to examine the prognostic value of FAR in patients with UCs.</p><p><strong>Materials and methods: </strong>Eligible articles were identified by searching PubMed, Web of Science, Embase, and the Cochrane Library until 15 January 2026. The prognostic value of FAR in UCs was evaluated by calculating pooled hazard ratios (HRs) with 95% confidence intervals (CIs). The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS).</p><p><strong>Results: </strong>Seven articles with 1996 patients were included in this meta-analysis. A high FAR significantly predicted poor OS (HR = 2.52, 95%CI = 2.04-3.11, <i>p</i> < 0.001) and unfavorable PFS (HR = 2.84, 95%CI = 2.22-3.64, <i>p</i> < 0.001) in patients with UCs. In the subgroup analyses, the predictive value of FAR for OS and PFS was not affected by study center, country, cancer type, tumor-node-metastasis stage, threshold, threshold analysis, or survival analysis (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Our findings show that a higher FAR significantly predicted unfavorable OS and inferior PFS for patients with UCs, suggesting that FAR is a promising biomarker for predicting UC prognosis.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149294670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lucia Belloni, Martina Bonacini, Alessandro Rossi, Giulia Besutti, Nicola Facciolongo, Sergio Mezzadri, Giovanni Dolci, Lucia Spaggiari, Carlo Salvarani, Stefania Croci, Alessandro Zerbini
{"title":"Circulating calprotectin levels are associated with lung damage and disease outcome in patients with COVID-19.","authors":"Lucia Belloni, Martina Bonacini, Alessandro Rossi, Giulia Besutti, Nicola Facciolongo, Sergio Mezzadri, Giovanni Dolci, Lucia Spaggiari, Carlo Salvarani, Stefania Croci, Alessandro Zerbini","doi":"10.1080/17520363.2026.2752503","DOIUrl":"https://doi.org/10.1080/17520363.2026.2752503","url":null,"abstract":"<p><strong>Objective: </strong>The present study aimed to investigate whether circulating calprotectin levels were associated with the extent of lung parenchyma involvement, laboratory parameters of inflammation/organ damage, and clinical outcome in patients with SARS-CoV-2 infection.</p><p><strong>Methods: </strong>A retrospective observational cohort study was conducted enrolling 172 adult patients with laboratory-confirmed SARS-CoV-2 infection. The extent of lung parenchyma involvement was assessed using a validated high-resolution computerized tomography (HRCT)-based stratification system. Serum calprotectin concentrations were quantified using the QUANTA Flash Circulating Calprotectin Reagents. Routine laboratory parameters were collected from clinical records. In a subset of patients who received tocilizumab (<i>n</i> = 56), serum samples were longitudinally collected.</p><p><strong>Results: </strong>Circulating serum calprotectin levels were significantly associated with the extent of CT-assessed pulmonary involvement, markers of systemic inflammation, and adverse clinical outcomes (mechanical ventilation requirement and in-hospital death). A calprotectin threshold of 3.86 μg/mL showed high sensitivity for identifying patients with ≥40% lung parenchyma involvement, while a threshold of 13.73 μg/mL showed high specificity for adverse clinical outcomes. Longitudinal monitoring of calprotectin in tocilizumab-treated patients revealed that rising levels during follow-up were associated with death or tracheotomy, independent of baseline values.</p><p><strong>Conclusion: </strong>Our findings support the clinical utility of circulating calprotectin as a complementary biomarker in COVID-19 management.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association between <i>IRAK1</i> gene rs1059703 polymorphism and rheumatoid arthritis risk.","authors":"Zheng Wang, Junhong Li","doi":"10.1080/17520363.2026.2750231","DOIUrl":"https://doi.org/10.1080/17520363.2026.2750231","url":null,"abstract":"<p><strong>Objectives: </strong>This meta-analysis aimed to investigate the relationship between interleukin-1 receptor-associated kinase (<i>IRAK1</i>) gene rs1059703 and rheumatoid arthritis (RA) risk.</p><p><strong>Methods: </strong>The pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated. Funnel plot with trim-and-fill analysis was used for publication bias investigation.</p><p><strong>Results: </strong><i>IRAK1</i> gene rs1059703 was not significantly associated with RA risk under dominant genetic model (OR = 1.47, 95%CI = 0.96-2.24, <i>p</i> = 0.071), recessive genetic model (OR = 1.14, 95%CI = 0.92-1.40, <i>p</i> = 0.2258), allele genetic model (OR = 1.29, 95%CI = 0.95-1.75, <i>p</i> = 0.0878), and codominant genetic model (OR = 1.33, 95%CI = 0.82-2.15, <i>p</i> = 0.2125). Subgroup analysis also suggested that <i>IRAK1</i> gene rs1059703 polymorphism was correlated with RA risk under dominant genetic model (I<sup>2</sup> = 80.9%, P<sub>Q</sub> < 0.0001, OR = 1.77, 95%CI = 1.12-2.79, <i>p</i> = 0.014) and allele model (I<sup>2</sup> = 79.6%, P<sub>Q</sub> = 0.0002, OR = 1.45, 95%CI = 1.05-2.00, <i>p</i> = 0.026) in Caucasian. Sensitivity analysis indicated that there was no significant change in the combined OR. No publication bias was observed.</p><p><strong>Conclusion: </strong>A statistically significant association between <i>IRAK1</i> rs1059703 and RA risk was observed in Caucasian populations, but not in Asian populations with the available power under the current sample size. The apparent Caucasian association observed in the full dataset was not sustained after restricting analyses to HWE-compliant studies, where only a single Caucasian study remained.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}